Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?-Reference-Cited by-同舟云学术

Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

Published:2018-12 Issue:12 Volume:36 Page:1146-1149
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Aboy Mateo,Crespo Cristina,Liddell Kathleen,Liddicoat Johnathon,Jordan Matthew

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/nbt.4308.pdf

Reference21 articles.

1. Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).

2. Schor, G.A., Norviel, V. & Cohen, I.G. Brief for amicus curiae Eric S. Lander in support of neither party http://hdl.handle.net/10161/7590 (2013).

3. Gold, R.E., Cook-Deegan, R. & Bubela, T. Sci. Transl. Med. 5, 192ed9 (2013).

4. Dilenge, T. et al. Brief for amicus curiae The Biotechnology Industry Organization in support of respondents https://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/briefs-v2/12-398_resp_amcu_bio.authcheckdam.pdf (2013).

5. Rai, A.K. & Cook-Deegan, R. Science 341, 137–138 (2013).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Myriad Decision at 10;Annual Review of Genomics and Human Genetics;2024-08-27

2. European patent protection for medical uses of known products and drug repurposing;Nature Biotechnology;2022-04

3. Mapping the European patent landscape for medical uses of known products;Nature Biotechnology;2021-11

4. One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?;Nature Biotechnology;2020-03

5. Reply to C.D. Richter;European Journal of Human Genetics;2020-02-17